Novo Nordisk Warns FDA of Biosimilar Delivery Safety Fears

In-PharmaTechnologist (04/17/12) Taylor, Nick
Novo Nordisk has told the FDA that allowing alternative delivery devices for biosimilars creates "significant safety implications." FDA draft guidance released earlier in the year allows biosimilars to use different drug delivery devices than their reference products.

Read the complete article

Share |

Sponsor Highlights